Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma or acral melanoma.

Principal Investigator

  • Harlan Pinto

Stanford Investigator(s)

  • Sunil Reddy
  • Susan M. Swetter, MD


Primary Contact:
Jennifer Wong
(650) 723-1002